Compound C108 is an inhibitor of the GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2), which is involved in breast tumor initiation. In a mouse xenograft model of breast cancer, compound C108 (1 μM for 24 hours) reduces the proportion of tumor-initiating cells approximately 10-fold compared with untreated cells. In MDA-MB-453 cells, and in the patient-derived xenograft cell line MAXF 401, it diminishes mammosphere formation.

15533-09-2

C15H14N2O3

270.28

DMF:PBS(pH 7.2)(1:6):0.14 mg/mL
DMSO:1 mg/mL
DMF:1 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years